Close

Oppenheimer Defends Acasti Pharma (ACST), Seeing Buying Opportunity

December 26, 2019 7:21 AM EST Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $7.00 price target on Acasti Pharma (NASDAQ: ACST)The analyst comments "With ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login